Although there are effective treatments available for patients with positive breast cancer, there are few treatment options for patients with negative triple breast cancer, who lack estrogen and progesterone receptors.

With the continued hope of finding a cure for cancer, researchers at the University of Texas have manufactured a new molecule that kills a wide range of difficult-to-treat cancers, including negative triple breast cancer.

The new enzyme strains the endoplasmic network, a complex network of ambobic membranes found inside the real-nucleus cell cytoplasm, leading to cell death, opening a large therapeutic window, with no adverse effects on normal mammal phenomenal cells.

Jong Mo An, a co-author of the study, designed small molecules targeting protein interactions in cells.

Jung and his colleagues tested a new enzyme called ERX-41, which affects breast cancer cells, both those containing estrogen receptors and those without.

The study, published on GeN, indicates that ERX-41 does not kill healthy cells, but eliminates cancer cells regardless of whether they contain estrogen receptors.

"It took us several years to chase the protein that was affected by exactly ERX-41, and that was the hard part, we sought many blocked ways, but we didn't give up," Jong Mo An said.

He continued: "Triple negative breast cancer is particularly pernicious, it targets women at younger ages, it is aggressive and resistant to treatment, I am really glad that we have discovered something that has the potential to make a big difference to these patients."